Rabbit anti-Human CD137 Monoclonal Antibody | anti-TNFRSF9 antibody

Recombinant Anti-CD137 Antibody (FITC), Rabbit Monoclonal

Cat. Num. AAA8100341

• Gene Names: TNFRSF9; ILA; 4-1BB; CD137; CDw137
• Reactivity: Human
• Applications: Flow Cytometry, Functional Assay
• Purity: Protein A
• Synonyms: CD137; Monoclonal Antibody; Recombinant Anti-CD137 Antibody (FITC); Rabbit Monoclonal; CD137 Antibody (FITC); Rabbit MAb; tumor necrosis factor receptor superfamily; member 9; Anti-4-1BB Antibody; Anti-CD137 Antibody; Anti-CDw137 Antibody; Anti-ILA Antibody; anti-TNFRSF9 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: Rabbit IgG
• Clone Number: A24
• Specificity: Human CD137
• Purity/Purification: Protein A
• Form/Format: Liquid; Aqueous solution containing 0.5% BSA and 0.03%ProClin300
• Concentration: 10ul/Test, 0.1mg/ml (varies by lot)

• Applicable Applications for anti-TNFRSF9 antibody: Flow Cytometry (FC/FACS/FCM)
• Antibody Type: Recombinant Antibody
• Immunogen: Recombinant Human CD137 Protein
• Conjugation: FITC
• Preparation: This antibody was obtained from a rabbit immunized with purified, recombinant Human CD137 (rh CD137) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.
• Preparation and Storage: This antibody can be stored at 2-8 degree C for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze!

Flow Cytometry (FC/FACS)

(Flow cytometric analysis of Human CD137 expression on human whole blood lymphocytes. Cells were stained with FITC-conjugated anti-Human CD137. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes.)

Related Product Information for anti-TNFRSF9 antibody

CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor-associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Soluble forms of CD137 (sCD137) are generated by differential splicing. sCD137 can bind to CD137 ligand to antagonize the costimulatory activities of the membrane-bound CD137 and reduce T cell proliferation and IL-2 secretion.

Product Categories/Family for anti-TNFRSF9 antibody

Cancer Drug Targets

References

Sica G, et al. (1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9.Nam KO, et al. (2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63.Wang Q, et al. (2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200.Melero I, et al. (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90.Thum E, et al. (2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.

NCBI and Uniprot Product Information

• NCBI GI #: 5730095
• NCBI GeneID: 3604
• NCBI Accession #: NP_001552.2
• NCBI GenBank Nucleotide #: NM_001561.5
• UniProt Accession #: Q07011; AAB34924
• Molecular Weight: 27,899 Da
• NCBI Official Full Name: tumor necrosis factor receptor superfamily member 9
• NCBI Official Synonym Full Names: tumor necrosis factor receptor superfamily, member 9
• NCBI Official Symbol: TNFRSF9
• NCBI Official Synonym Symbols: ILA; 4-1BB; CD137; CDw137
• NCBI Protein Information: tumor necrosis factor receptor superfamily member 9; CD137 antigen; T cell antigen ILA; T-cell antigen ILA; 4-1BB ligand receptor; homolog of mouse 4-1BB; receptor protein 4-1BB; T-cell antigen 4-1BB homolog; induced by lymphocyte activation (ILA); interl
• UniProt Protein Name: Tumor necrosis factor receptor superfamily member 9
• Protein Family: Tumor necrosis factor receptor superfamily
• UniProt Gene Name: TNFRSF9
• UniProt Synonym Gene Names: CD137; ILA
• UniProt Entry Name: TNR9_HUMAN

NCBI Description

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses. The expression of this receptor is induced by lymphocyte activation. TRAF adaptor proteins have been shown to bind to this receptor and transduce the signals leading to activation of NF-kappaB. [provided by RefSeq, Jul 2008]

Uniprot Description

TNFRSF9: Receptor for TNFSF9/4-1BBL. Possibly active during T cell activation.

Protein type: Membrane protein, integral; Receptor, misc.

Chromosomal Location of Human Ortholog: 1p36

Cellular Component: extracellular space; integral to plasma membrane; external side of plasma membrane

Molecular Function: cytokine binding; receptor activity

Biological Process: negative regulation of cell proliferation; apoptosis